NEW INDICATIONS

Keytruda plus Chemotherapy FDA Approved for First-Line Treatment of Cervical Cancer

JHOP - December 2021 Vol 11, No 6 - FDA Oncology Update
Download PDF

On October 13, 2021, the FDA accelerated the approval of pembrolizumab (Keytruda; Merck), in combination with chemotherapy, with or without bevacizumab (Avastin), for the treatment of patients with persistent, recurrent, or metastatic cervical cancer who have not received chemotherapy and whose tumors express PD-L1 ≥1%, as determined by an FDA-approved test.

At the same time, the FDA also granted regular approval to pembrolizumab as a single agent for patients with recurrent or metastatic cervical cancer whose disease progressed during or after chemotherapy and PD-L1 expression ≥1%, as determined by an FDA-approved test. In June 2018, the FDA accelerated the approval of this indication to pembrolizumab.

The approval of first-line pembrolizumab plus chemotherapy indication was based on the KEYNOTE-826 study, a multicenter, randomized, double-blind, placebo-controlled clinical trial. The study included 617 patients with persistent, recurrent, or first-line metastatic cervical cancer who had not received chemotherapy. Patients were enrolled regardless of a PD-L1 expression status. Patients were randomized in a 1:1 ratio to pembrolizumab plus paclitaxel and cisplatin or paclitaxel and carboplatin, with or without bevacizumab, or to placebo plus chemotherapy, with or without bevacizumab. Pembrolizumab therapy continued until disease progression, unacceptable adverse events, or completion of 24-month treatment.

The main efficacy measures were overall survival (OS) and progression-free survival (PFS). Secondary measures were objective response rate (ORR) and duration of response (DOR).

For the 548 patients with tumors expressing PD-L1 ≥1%, the median OS was not reached (NR; 95% confidence interval [CI], 19.8-NR) in the pembrolizumab arm versus 16.3 months (95% CI, 14.5-19.4) in the placebo arm (hazard ratio [HR], 0.64; 95% CI, 0.50-0.81; 1-sided P = .0001). The median PFS was 10.4 months (95% CI, 9.7-12.3) in the pembrolizumab arm and 8.2 months (95% CI, 6.3-8.5) in the placebo arm (HR, 0.62; 95% CI, 0.50-0.77; 1-sided P <.0001). The ORR was 68% and 50%, and the median DOR was 18 months and 10.4 months, respectively.

The most common (≥20%) adverse reactions in the pembrolizumab arm were peripheral neuropathy, alopecia, anemia, fatigue/asthenia, nausea, neutropenia, diarrhea, hypertension, thrombocytopenia, constipation, arthralgia, vomiting, urinary tract infection, rash, leukopenia, hypothyroidism, and decreased appetite.

Related Items
FDA-Approved Nirogacestat Demonstrates Improved Patient Outcomes in Desmoid Tumor Management
Web Exclusives published on February 12, 2024 in FDA Oncology Update
Iwilfin FDA Approved for Adults and Pediatric Patients with High-Risk Neuroblastoma
Web Exclusives published on January 17, 2024 in FDA Oncology Update
Welireg Now FDA Approved for Patients with Advanced Renal Cell Carcinoma
Web Exclusives published on January 17, 2024 in FDA Oncology Update
Keytruda Plus Chemotherapy Receives New FDA Approvals for Advanced Biliary Tract Cancer and 2 Forms of Advanced Gastroesophageal Junction Adenocarcinoma
Web Exclusives published on December 19, 2023 in FDA Oncology Update
FDA Approved Loqtorzi, a PD-1 Inhibitor, for the Treatment of Adults With Metastatic or Recurrent Nasopharyngeal Carcinoma
Web Exclusives published on December 18, 2023 in FDA Oncology Update
Tibsovo FDA Approved for Patients With Relapsed Myelodysplastic Syndromes and IDH1 Mutation
Web Exclusives published on December 18, 2023 in FDA Oncology Update
Fruzaqla FDA Approved for Refractory Metastatic Colorectal Cancer
JHOP - December 2023 Vol 13, No 6 published on December 6, 2023 in FDA Oncology Update
Rozlytrek Now Approved for Pediatric Patients Older Than 1 Month With Solid Tumors and NTRK Gene Fusion and in New Oral Pellet Form
JHOP - December 2023 Vol 13, No 6 published on December 6, 2023 in FDA Oncology Update
FDA Authorizes Updated COVID-19 Vaccine Formulations for Better Protection Against Current Variants
JHOP - December 2023 Vol 13, No 6 published on November 17, 2023 in FDA Oncology Update
Bosulif Now FDA Approved for Pediatric Patients With Chronic Myelogenous Leukemia
JHOP - December 2023 Vol 13, No 6 published on November 3, 2023 in FDA Oncology Update
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: